{
    "clinical_study": {
        "@rank": "168228", 
        "arm_group": {
            "arm_group_label": "Acetogenins", 
            "arm_group_type": "Experimental", 
            "description": "Acetogenins twice (BID) per day for 12 months"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to confirm the findings of an early study with prostate cancer\n      and to expand our knowledge of treating prostate cancer using an\n      Adenosine-5'-triphosphate(ATP)inhibitor."
        }, 
        "brief_title": "Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate (ATP) Inhibitor", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of prostate cancer\n\n          -  Referred to the study by their treating physician\n\n        Exclusion Criteria:\n\n        - Any type of treatment before starting study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987999", 
            "org_study_id": "GEN9892131"
        }, 
        "intervention": {
            "arm_group_label": "Acetogenins", 
            "intervention_name": "Acetogenins", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Adenosine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 11, 2014", 
        "number_of_arms": "1", 
        "official_title": "Phase II Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate(ATP)Inhibitor.", 
        "overall_official": {
            "affiliation": "Optimal Health Research", 
            "last_name": "Steven Osguthorpe, ND", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.", 
            "measure": "Gleason Score", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Prostate Specific  Antigens (PSA)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Optimal Health Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Optimal Health Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}